Drug Price Control Limit At Rs 25 Crore

Image
BUSINESS STANDARD
Last Updated : Feb 26 2013 | 12:54 AM IST

The government unveiled details of a new pharmaceuticals policy on Friday that aims to reduce state control on drug pricing and encourage research. But industry officials accorded it a tepid welcome, saying it did not go far enough.

Under the new policy the government will fix prices of only those bulk drugs whose formulations have an annual turnover of Rs 25 crore and in which a single firm making a formulation has a market share of 50 per cent or more.

But it will also fix prices of formulations with a turnover of Rs 10-25 crore if a single formulator has a market share of 90 per cent or more.

The earlier thresholds were Rs 4 crore if any formulator had more than a 50 per cent market share or Rs 1 crore if a formulator had a 90 per cent or more market share.

The new measures are expected to reduce by half the number of drugs whose prices the government now determines, currently at 74. But Friday's announcement did not say which drugs would be on the pruned list, information the industry is keenly awaiting.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 16 2002 | 12:00 AM IST

Next Story